Nodal status in predicting the outcome of treatment with definitive chemoradiation in patients with cervical cancer in FIGO IIIC1 and IIIC2 stages.

IF 2 Q4 ONCOLOGY
Reports of Practical Oncology and Radiotherapy Pub Date : 2026-02-27 eCollection Date: 2026-01-01 DOI:10.5603/rpor.109848
Marija Živković Radojević, Katarina Janković, Marko Folić, Marko Spasić, Vladan Marković, Dragan Lončar, Pavle Petković, Radiša Vojinović, Neda Milosavljević
{"title":"Nodal status in predicting the outcome of treatment with definitive chemoradiation in patients with cervical cancer in FIGO IIIC1 and IIIC2 stages.","authors":"Marija Živković Radojević, Katarina Janković, Marko Folić, Marko Spasić, Vladan Marković, Dragan Lončar, Pavle Petković, Radiša Vojinović, Neda Milosavljević","doi":"10.5603/rpor.109848","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 2018 International Federation of Gynecology and Obstetrics (FIGO) classification redefined stage III of locally advanced cervical cancer into substages IIIC1 pelvic and IIIC2 para-aortic lymphadenopathy, ignoring the number and size of lymph nodes. The aim was to analyse of the volume burden influence of the primary tumor and pathological lymph nodes, on the three-year overall survival (OS) and progression free survival (PFS), in cervical cancer patients FIGO stages IIIC1 and IIIC2 treated with definitive chemoradiation.</p><p><strong>Materials and methods: </strong>A retrospective clinical study based on the analysis of three-year OS, PFS and factors that may influence the time to disease progression in cervical cancer patients in FIGO IIIC1 and IIIC2 stages treated from January 2020 to January 2024 with external beam radiotherapy (EBRT) with simultaneous integrated or sequential boost doses, brachytherapy and chemopotentiation at the Radiation Oncology Center of the UCC Kragujevac.</p><p><strong>Results: </strong>The study included 92 patients whose three-year OS was 68.5%, while PFS was 57.6%. The influence of age, comorbidity, belonging to stage IIIC1 or IIIC2, pathohistological tumor characteristics, number, total volume (GTVn) or the presence of a conglomerate of lymph nodes, tumor volume (GTVt), treatment duration over 56 days and radiotherapy technique on the length of PFS was examined. The length of PFS is influenced by treatment duration over 56 days, GTVn, number and conglomeration of lymph nodes, and EBRT dose (p < 0.05).</p><p><strong>Conclusions: </strong>The number and total volume of lymph nodes have a statistically significant effect on the length of PFS in FIGO stage IIIC1 and IIIC2 cervical cancer patients treated with definitive chemoradiation.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"96-106"},"PeriodicalIF":2.0000,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046405/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology and Radiotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/rpor.109848","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The 2018 International Federation of Gynecology and Obstetrics (FIGO) classification redefined stage III of locally advanced cervical cancer into substages IIIC1 pelvic and IIIC2 para-aortic lymphadenopathy, ignoring the number and size of lymph nodes. The aim was to analyse of the volume burden influence of the primary tumor and pathological lymph nodes, on the three-year overall survival (OS) and progression free survival (PFS), in cervical cancer patients FIGO stages IIIC1 and IIIC2 treated with definitive chemoradiation.

Materials and methods: A retrospective clinical study based on the analysis of three-year OS, PFS and factors that may influence the time to disease progression in cervical cancer patients in FIGO IIIC1 and IIIC2 stages treated from January 2020 to January 2024 with external beam radiotherapy (EBRT) with simultaneous integrated or sequential boost doses, brachytherapy and chemopotentiation at the Radiation Oncology Center of the UCC Kragujevac.

Results: The study included 92 patients whose three-year OS was 68.5%, while PFS was 57.6%. The influence of age, comorbidity, belonging to stage IIIC1 or IIIC2, pathohistological tumor characteristics, number, total volume (GTVn) or the presence of a conglomerate of lymph nodes, tumor volume (GTVt), treatment duration over 56 days and radiotherapy technique on the length of PFS was examined. The length of PFS is influenced by treatment duration over 56 days, GTVn, number and conglomeration of lymph nodes, and EBRT dose (p < 0.05).

Conclusions: The number and total volume of lymph nodes have a statistically significant effect on the length of PFS in FIGO stage IIIC1 and IIIC2 cervical cancer patients treated with definitive chemoradiation.

FIGO IIIC1和IIIC2期宫颈癌患者淋巴结状态预测终期放化疗结果
背景:2018年国际妇产科联合会(FIGO)分类将局部晚期宫颈癌的III期重新定义为IIIC1期盆腔和IIIC2期腹主动脉旁淋巴结病,忽略了淋巴结的数量和大小。目的是分析原发性肿瘤和病理淋巴结的体积负担对FIGO IIIC1期和IIIC2期宫颈癌患者接受最终放化疗的三年总生存期(OS)和无进展生存期(PFS)的影响。材料和方法:一项回顾性临床研究,基于对2020年1月至2024年1月期间在UCC Kragujevac放射肿瘤学中心接受同时综合或顺序增强剂量、近距离放疗和化学增强的外束放疗(EBRT)治疗的FIGO IIIC1和IIIC2期宫颈癌患者的三年OS、PFS和可能影响疾病进展时间的因素的分析。结果:研究纳入92例患者,三年OS为68.5%,PFS为57.6%。研究年龄、合并症(IIIC1期或IIIC2期)、肿瘤病理组织学特征、数量、总体积(GTVn)或淋巴结丛状的存在、肿瘤体积(GTVt)、治疗时间超过56天以及放疗技术对PFS长度的影响。PFS的长短受治疗时间56 d、GTVn、淋巴结数目和聚集、EBRT剂量的影响(p < 0.05)。结论:FIGO IIIC1期和IIIC2期宫颈癌患者接受终期放化疗后,淋巴结数量和总体积对PFS长度有统计学意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
8.30%
发文量
115
审稿时长
16 weeks
期刊介绍: Reports of Practical Oncology and Radiotherapy is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment. Reports of Practical Oncology and Radiotherapy is a journal of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists and the Greater Poland Cancer Centre, affiliated with the Spanish Society of Radiotherapy and Oncology, the Italian Association of Radiotherapy and the Portuguese Society of Radiotherapy - Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书